Document Detail

The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
MedLine Citation:
PMID:  14534885     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown. METHODS: The authors evaluated sCD86 levels by enzyme-linked immunosorbent assay in patients with acute myeloid leukemia (AML) (n = 57 patients) and patients with myelodysplastic syndrome (MDS) (n = 40 patients) and analyzed the relation between sCD86 levels and various clinical parameters. RESULTS: Levels of sCD86 were elevated (> 2.32 ng/mL) relative to normal donors (0.22-2.32 ng/mL; n = 51 patients) in 25% of patients with AML and in 27% of patients with MDS. Patients with AML who had elevated sCD86 levels had significantly lower complete remission (CR) rates compared with patients with AML who had normal sCD86 levels. In multivariate analysis using sCD86 as a continuous variable and including the interaction of age and sCD86 as a variable, sCD86 was a significant prognostic factor (P = 0.014) independent of cytogenetics. Further analysis demonstrated that, in patients with AML age 60 years and younger, but not in patients older than 60 years, elevated sCD86 levels were associated with significantly shorter survival (P = 0.04). There was no correlation between sCD86 levels and CR rates or survival in patients with MDS. CONCLUSIONS: The presence in patients with AML of elevated levels of circulating sCD86 were associated with lower CR rates and poor survival. The prognostic significance of sCD86 was independent of cytogenetics but was modulated by age, in that it was independently significant only in younger patients. The results suggest that sCD86 may play a role in modulating immune responses associated with the progression of AML.
Barry D Hock; Judith L McKenzie; William Nigel Patton; Lisa F Haring; Ying Yang; Yu Shen; Elihu H Estey; Maher Albitar
Related Documents :
3290825 - Transient opacification of the urinary pathways by amorphous debris in children with le...
4016715 - Karyotypic evolution in multiple myeloma.
59435 - Leukapheresis of patients with chronic granulocytic leukemia (cgl), using the haemoneti...
20427085 - Hypoplastic myelodysplastic syndrome (h-mds) is a distinctive clinical entity with poor...
22814645 - Glycomic analysis of tear and saliva in ocular rosacea patients: the search for a bioma...
6333945 - Cytokines and the chronic inflammation of rheumatic disease. ii. the presence of interl...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  98     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-09     Completed Date:  2003-10-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1681-8     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2003 American Cancer Society.
Haematology Research Group, Christchurch Hospital, Christchurch, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / blood*
Antigens, CD86
Leukemia, Myeloid, Acute / blood*,  mortality
Membrane Glycoproteins / blood*
Middle Aged
Myelodysplastic Syndromes / blood*,  mortality
Survival Rate
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, CD86; 0/CD86 protein, human; 0/Membrane Glycoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  National Cancer Data Base report on osteosarcoma of the head and neck.
Next Document:  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangioc...